Cargando…

1470. Linezolid for Treatment of Urinary Tract Infections Caused by Vancomycin-resistant Enterococci

BACKGROUND: Urinary tract infections (UTI) caused by vancomycin-resistant enterococcus (VRE) are difficult to manage due to lack of effective oral treatment options. Linezolid is an antibiotic with activity against VRE that is available orally, but only 30% of each dose is excreted in the urine. Dat...

Descripción completa

Detalles Bibliográficos
Autores principales: Pontefract, Benjamin, Madaras-Kelly, Karl
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6809927/
http://dx.doi.org/10.1093/ofid/ofz360.1334
_version_ 1783462119953399808
author Pontefract, Benjamin
Madaras-Kelly, Karl
author_facet Pontefract, Benjamin
Madaras-Kelly, Karl
author_sort Pontefract, Benjamin
collection PubMed
description BACKGROUND: Urinary tract infections (UTI) caused by vancomycin-resistant enterococcus (VRE) are difficult to manage due to lack of effective oral treatment options. Linezolid is an antibiotic with activity against VRE that is available orally, but only 30% of each dose is excreted in the urine. Data on the efficacy of linezolid in the treatment of UTI is limited. The purpose of this analysis was to assess the comparative efficacy of linezolid to other VRE-active antibiotics in the treatment of UTI. METHODS: A national retrospective cohort of inpatient veterans with a positive urine culture for VRE during years 2013 through 2018 was developed. Patient demographics, vital signs, urinary symptoms, antibiotics prescribed, and 14-day post-treatment outcomes were collected. Patients without UTI symptoms, urine cultures with < 10(5) CFU/mL (<10(3) CFU/mL for catheterized patients), or patients not treated with VRE-active antibiotics were excluded. Odds ratios were used to compare linezolid and non-linezolid antibiotics for 14-day VRE bacteriuria, UTI retreatment, and death endpoints. RESULTS: Of 3,846 urine cultures identified with VRE, 624 (16%) patients were eligible for evaluation of UTI symptoms. Of these, 92/624 (15%) met study criteria. The primary reason for exclusion was asymptomatic bacteriuria [339/532 (64%)]. Linezolid was prescribed in 54/92 (59%) of cases. Comparators included penicillin’s [12/92 (13%)], nitrofurantoin [11/92 (12%)], daptomycin [7/92 (8%)], tetracycline’s [6/92 (7%)], and others [2/92 (2%)]. Between linezolid and comparator groups, mean (+S.D.) patient age [70 (12) vs. 68 (13) years, P = 0.45] and Charlson Comorbidity Index [8.9 (3.1) vs. 8.3 (3.5), P = 0.39] were similar. Negative outcomes were uncommon: 7% VRE bacteriuria, 8% UTI re-treatment, 4% death. No difference in [(OR) +95% CI] between linezolid and comparators was observed: positive VRE bacteriuria [0.3 (0.1, 1.9), P = 0.20], UTI retreatment [1.8 (0.3, 10.0), P = 0.49], death [1.4 (0.1, 16.1), P = 0.79]. CONCLUSION: Most patients with a VRE positive urine culture who received antibiotics did not meet diagnostic criteria for UTI, and negative outcomes were uncommon. Linezolid and comparator regimens with VRE activity were effective for treating mild VRE UTI. DISCLOSURES: All authors: No reported disclosures.
format Online
Article
Text
id pubmed-6809927
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-68099272019-10-28 1470. Linezolid for Treatment of Urinary Tract Infections Caused by Vancomycin-resistant Enterococci Pontefract, Benjamin Madaras-Kelly, Karl Open Forum Infect Dis Abstracts BACKGROUND: Urinary tract infections (UTI) caused by vancomycin-resistant enterococcus (VRE) are difficult to manage due to lack of effective oral treatment options. Linezolid is an antibiotic with activity against VRE that is available orally, but only 30% of each dose is excreted in the urine. Data on the efficacy of linezolid in the treatment of UTI is limited. The purpose of this analysis was to assess the comparative efficacy of linezolid to other VRE-active antibiotics in the treatment of UTI. METHODS: A national retrospective cohort of inpatient veterans with a positive urine culture for VRE during years 2013 through 2018 was developed. Patient demographics, vital signs, urinary symptoms, antibiotics prescribed, and 14-day post-treatment outcomes were collected. Patients without UTI symptoms, urine cultures with < 10(5) CFU/mL (<10(3) CFU/mL for catheterized patients), or patients not treated with VRE-active antibiotics were excluded. Odds ratios were used to compare linezolid and non-linezolid antibiotics for 14-day VRE bacteriuria, UTI retreatment, and death endpoints. RESULTS: Of 3,846 urine cultures identified with VRE, 624 (16%) patients were eligible for evaluation of UTI symptoms. Of these, 92/624 (15%) met study criteria. The primary reason for exclusion was asymptomatic bacteriuria [339/532 (64%)]. Linezolid was prescribed in 54/92 (59%) of cases. Comparators included penicillin’s [12/92 (13%)], nitrofurantoin [11/92 (12%)], daptomycin [7/92 (8%)], tetracycline’s [6/92 (7%)], and others [2/92 (2%)]. Between linezolid and comparator groups, mean (+S.D.) patient age [70 (12) vs. 68 (13) years, P = 0.45] and Charlson Comorbidity Index [8.9 (3.1) vs. 8.3 (3.5), P = 0.39] were similar. Negative outcomes were uncommon: 7% VRE bacteriuria, 8% UTI re-treatment, 4% death. No difference in [(OR) +95% CI] between linezolid and comparators was observed: positive VRE bacteriuria [0.3 (0.1, 1.9), P = 0.20], UTI retreatment [1.8 (0.3, 10.0), P = 0.49], death [1.4 (0.1, 16.1), P = 0.79]. CONCLUSION: Most patients with a VRE positive urine culture who received antibiotics did not meet diagnostic criteria for UTI, and negative outcomes were uncommon. Linezolid and comparator regimens with VRE activity were effective for treating mild VRE UTI. DISCLOSURES: All authors: No reported disclosures. Oxford University Press 2019-10-23 /pmc/articles/PMC6809927/ http://dx.doi.org/10.1093/ofid/ofz360.1334 Text en © The Author(s) 2019. Published by Oxford University Press on behalf of Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Abstracts
Pontefract, Benjamin
Madaras-Kelly, Karl
1470. Linezolid for Treatment of Urinary Tract Infections Caused by Vancomycin-resistant Enterococci
title 1470. Linezolid for Treatment of Urinary Tract Infections Caused by Vancomycin-resistant Enterococci
title_full 1470. Linezolid for Treatment of Urinary Tract Infections Caused by Vancomycin-resistant Enterococci
title_fullStr 1470. Linezolid for Treatment of Urinary Tract Infections Caused by Vancomycin-resistant Enterococci
title_full_unstemmed 1470. Linezolid for Treatment of Urinary Tract Infections Caused by Vancomycin-resistant Enterococci
title_short 1470. Linezolid for Treatment of Urinary Tract Infections Caused by Vancomycin-resistant Enterococci
title_sort 1470. linezolid for treatment of urinary tract infections caused by vancomycin-resistant enterococci
topic Abstracts
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6809927/
http://dx.doi.org/10.1093/ofid/ofz360.1334
work_keys_str_mv AT pontefractbenjamin 1470linezolidfortreatmentofurinarytractinfectionscausedbyvancomycinresistantenterococci
AT madaraskellykarl 1470linezolidfortreatmentofurinarytractinfectionscausedbyvancomycinresistantenterococci